Dato-DXd
Lung Cancer
First-in-human, phase I dose-escalation and dose-expansion study of trophoblast cell-surface antigen 2-directed antibody-drug conjugate datopotamab deruxtecan in non-small-cell lung cancer: TROPION-PanTumor01
Shimizu T, Sands J, Yoh K, et al.
J Clin Oncol. 2023;41(29):4678-4687.
T-DXd
Colorectal Cancer
Final results of DESTINY-CRC01 investigating trastuzumab deruxtecan in patients with HER2-expressing metastatic colorectal cancer
Yoshino T, Di Bartolomeo M, Raghav K, et al.
Nat Commun. 2023;14(1):3332.
Pexidartinib
Other/Multi
Tenosynovial Giant Cell Tumor Observational Platform Project (TOPP) Registry: A 2-year analysis of patient-reported outcomes and treatment strategies
Palmerini E, Healey JH, Bernthal NM, et al.
Oncologist. 2023;28(6):e425-e435.
Edoxaban
Cardiovascular - AF
Edoxaban treatment in atrial fibrillation in routine clinical care: One-year outcomes of the prospective observational ETNA-AF study in South Korean patients
Choi E-K, Choi J-I, Park H-S, et al.
J Arrhythm. 2023;39(4):546-555.
Dato-DXd
Lung Cancer
TROPION-Lung08: Phase III study of datopotamab deruxtecan plus pembrolizumab as first-line therapy for advanced NSCLC
Levy B, Felip E, Reck M, et al.
Future Oncol. 2023;19(21):1461-1472.
HER3-DXd
Lung Cancer
HERTHENA-Lung01: A phase II study of patritumab deruxtecan (HER3-DXd) in previously treated metastatic EGFR-mutated NSCLC
Yu HA, Yang J C-H, Hayashi H, et al.
Future Oncol. 2023;19(19):1319-1329.
HER3-DXd
Breast Cancer
Patritumab deruxtecan in untreated hormone receptor-positive/HER2-negative early breast cancer: final results from part A of the window-of-opportunity SOLTI TOT-HER3 pre-operative study
Oliveira M, Falato C, Margelí Vila M, et al.
Ann Oncol. 2023;34(8):670-680.
T-DXd
Breast Cancer
Real-world perspectives and practices for pneumonitis/interstitial lung disease associated with trastuzumab deruxtecan use in human epidermal growth factor receptor 2-expressing metastatic breast cancer
Rugo HS, Crossno CL, Gesthalter YB, et al.
JCO Oncol Pract. 2023;19(8):539-546.
T-DXd
Breast Cancer
Newly approved and emerging agents in HER2-positive metastatic breast cancer
Graff SL, Yan F, Abdou Y.
Clin Breast Cancer. 2023;23(7):e380-e393.
T-DXd
Breast Cancer
Patient-reported outcomes and hospitalization data in patients with HER2-positive metastatic breast cancer receiving trastuzumab deruxtecan or trastuzumab emtansine in the phase III DESTINY-Breast03 study
Curigliano G, Dunton K, Rosenlund M, et al.
Ann Oncol. 2023;34(7):569-77.